Developing advanced technology to analyze antibodies for SARS-CoV-2
New Technology for High-Resolution Antibody Profiling for SARS-CoV-2
This study is working on a new way to closely examine how your immune system responds to COVID-19, including how vaccines help and what happens with long-COVID, so that doctors can provide better, more personalized care for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ambergen, INC NIH-funded |
| Lab location | 1 site (Watertown, United States) |
| Project ID | NIH-10686794 on NIH RePORTER |
What this research studies
This research focuses on creating a new technology for high-resolution antibody profiling specifically for the SARS-CoV-2 virus. By utilizing a mass spectrometric bead-array method, the project aims to enhance the understanding of the immune response to COVID-19, including the effects of vaccination and the development of long-COVID. The approach involves detailed analysis of antibodies to identify their structure and function, which could lead to improved diagnostics and treatments for COVID-19. Patients may benefit from more personalized and effective healthcare solutions based on their immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been infected with SARS-CoV-2, those experiencing long-COVID symptoms, and vaccinated individuals.
Not a fit: Patients who have not been infected with SARS-CoV-2 or have not received a COVID-19 vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostics and treatments for COVID-19 and its long-term effects.
How similar studies have performed: Other research has shown promise in antibody profiling technologies, indicating potential for success with this novel approach.
Where this research is happening
Watertown, United States
- Ambergen, INC — Watertown, United States (Active)
Researchers
- Principal investigator: Lim, Mark — Ambergen, INC
- Study coordinator: Lim, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.